BSE · 532154
Johnson Pharmacare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Shareholding
As of 2026-06-30
- Public100%
1,17,101 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
Not enough history.
52-week position
Where the current price sits in its yearly band
The band spans 1.94× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
- Reported zero revenue in 4 of the last 8 disclosed periods.
Peer comparison
Trading · ranked #346 of 693 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,63,802 Cr | 101.43 | 3.71 | 3.66% | 4.59% |
| Avenue Supermarts Limited | ₹2,24,349 Cr | 71.98 | 8.6 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,68,779 Cr | 88.12 | 21.69 | 24.4% | 8.62% |
| FSN E-Commerce Ventures Ltd. | ₹1,04,618 Cr | 314.83 | 63.16 | 19.49% | 2.85% |
| Aditya Infotech Limited | ₹50,886 Cr | 82.37 | 13.87 | 16.16% | 10.38% |
| Vishal Mega Mart Limited | ₹45,148 Cr | 50.19 | 5.7 | 11.37% | 6.45% |
| Aegis Logistics Limited | ₹42,976 Cr | 32.26 | 6.45 | 20.01% | 14.99% |
| Premier Energies Limited | ₹40,670 Cr | 22.98 | 7.88 | 34.23% | 19.11% |
| Redington Limited | ₹27,339 Cr | 13.62 | 2.54 | 18.62% | 1.31% |
| Honasa Consumer Limited | ₹16,378 Cr | 57.17 | 11.02 | 19.03% | 10.3% |
| Johnson Pharmacare Limited(this company) | ₹25 Cr | — | 57.5 | -9527.55% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashJohnson Pharmacare Limited, with a market capitalization of Rs 26 Cr, reported zero revenue for the most recent fiscal year. The company's book value is Rs 0.01 and its debt-to-equity ratio stands at 0.02. The 52-week high for its shares was Rs 0.88 and the low was Rs 0.47.
Positives
- +The debt-to-equity ratio is low at 0.02.
Negatives
- −The company reported zero revenue for March 2024 and March 2025.
- −Net profit was negative, at -Rs 0.1962 Cr in March 2024 and -Rs 0.5838 Cr in March 2025.
- −Return on Equity (ROE) is significantly negative at -9527.55%.
- −Return on Capital Employed (ROCE) is significantly negative at -188.68%.
- −Promoter holding is 0% as of March 2026.
- −The company is under surveillance measures including GSM and LT-ASM.
Financial Performance
For the fiscal year ending March 2024, Johnson Pharmacare Limited reported zero revenue, a decline from Rs 2.5269 Cr in March 2023. The net profit was -Rs 0.1962 Cr in March 2024, compared to -Rs 1.2914 Cr in March 2023. In March 2025, the company again reported zero revenue and a net profit of -Rs 0.5838 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is -9527.55%, and Return on Capital Employed (ROCE) is -188.68%. The profit margin for the most recent period is 0%. Earnings per share (EPS) for March 2024 stood at -Rs 0.0036 and further declined to -Rs 0.01 in March 2025.
Balance Sheet
Johnson Pharmacare Limited has a debt-to-equity ratio of 0.02, indicating a low level of debt relative to equity. The book value per share is Rs 0.01. No dividend yield was reported.
Ownership & Pledges
As of March 2026, public shareholding constitutes 100% of the total shares, with promoter holding at 0%. There are no shares held by DIIs or FIIs. The number of shareholders as of March 2026 was 117,101. No promoter pledges were reported.
Regulatory & Surveillance
Johnson Pharmacare Limited is under surveillance measures including GSM (Graded Surveillance Measure) and LT-ASM (Long Term Additional Surveillance Measure) at Stage 1. Specifically, it is categorized as 'GSM · GSM 0 · LT-ASM · ASM 1'.
Data as of — price: 2026-11-14 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Johnson Pharmacare Limitedshare price & fundamentals